Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Cardiol Therapeutics NASDAQ:CRDL$1.45 +0.14 (+10.69%) As of 06/4/2025 04:00 PM EasternCardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol TherapeuticsMarket Capitalization$108.22 millionP/E Ratio-3.72Consensus RatingBuyConsensus Price Target$8.67 (+497.7% Upside)Volume506,742 sharesAverage Volume355,774 shares Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. OS Therapies NYSE:OSTX$1.66 +0.07 (+4.40%) As of 06/4/2025 04:00 PM EasternOS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. More about OS TherapiesMarket Capitalization$46.64 millionP/E Ratio-1.93Consensus RatingBuyConsensus Price Target$18.00 (+984.3% Upside)Volume245,721 sharesAverage Volume463,968 shares3. Denison Mines NYSEAMERICAN:DNN$1.65 -0.04 (-2.37%) As of 06/4/2025 04:10 PM EasternDenison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison MinesMarket Capitalization$1.48 billionP/E Ratio-165.00Consensus RatingBuyConsensus Price Target$3.00 (+81.8% Upside)Volume141.70 million sharesAverage Volume37.77 million shares4. GeoVax Labs NASDAQ:GOVX$1.12 +0.07 (+6.67%) As of 06/4/2025 04:00 PM EasternGeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. More about GeoVax LabsMarket Capitalization$17.02 millionP/E Ratio-0.31Consensus RatingBuyConsensus Price Target$11.10 (+891.1% Upside)Volume291,794 sharesAverage Volume514,993 shares5. Quince Therapeutics NASDAQ:QNCX$1.09 +0.04 (+3.81%) As of 06/4/2025 04:00 PM EasternQuince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$49.56 millionP/E Ratio-0.88Consensus RatingBuyConsensus Price Target$8.00 (+633.9% Upside)Volume85,493 sharesAverage Volume287,195 shares6. Reviva Pharmaceuticals NASDAQ:RVPH$0.81 0.00 (-0.13%) As of 06/4/2025 04:00 PM EasternReviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$38.12 millionP/E Ratio-0.73Consensus RatingBuyConsensus Price Target$9.00 (+1,005.0% Upside)Volume392,352 sharesAverage Volume1.14 million shares7. Immunic NASDAQ:IMUX$0.78 +0.04 (+6.11%) As of 06/4/2025 04:00 PM EasternImmunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$74.26 millionP/E Ratio-0.63Consensus RatingBuyConsensus Price Target$11.60 (+1,396.8% Upside)Volume1.11 million sharesAverage Volume790,325 shares8. HIVE Digital Technologies NASDAQ:HIVE$1.94 +0.06 (+3.19%) As of 06/4/2025 04:00 PM EasternHIVE Digital Technologies Ltd. operates as a cryptocurrency mining company in Canada, Sweden, and Iceland. The company engages in the mining and sale of digital currencies, including Ethereum Classic, Bitcoin, and other coins. More about HIVE Digital TechnologiesMarket Capitalization$361.15 millionP/E Ratio-38.80Consensus RatingBuyConsensus Price Target$7.64 (+294.0% Upside)Volume14.51 million sharesAverage Volume7.35 million shares9. Western Copper & Gold NYSE:WRN$1.26 +0.05 (+4.13%) As of 06/4/2025 04:00 PM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$252 millionP/E Ratio-63.00Consensus RatingBuyConsensus Price Target$4.25 (+237.3% Upside)Volume314,899 sharesAverage Volume372,044 shares10. Ur-Energy NYSEAMERICAN:URG$0.83 +0.02 (+2.62%) As of 06/4/2025 04:10 PM EasternUr-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur-EnergyMarket Capitalization$302.20 millionP/E Ratio-6.38Consensus RatingBuyConsensus Price Target$2.30 (+177.1% Upside)Volume4.20 million sharesAverage Volume4.26 million shares11. Lucid Diagnostics NASDAQ:LUCD$1.22 -0.04 (-3.17%) As of 06/4/2025 04:00 PM EasternLucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$131.99 millionP/E Ratio-1.07Consensus RatingBuyConsensus Price Target$3.50 (+186.9% Upside)Volume968,581 sharesAverage Volume560,035 shares12. FibroBiologics NASDAQ:FBLG$0.85 +0.06 (+7.77%) As of 06/4/2025 04:00 PM EasternFibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologicsMarket Capitalization$32.52 millionP/E Ratio-4.05Consensus RatingBuyConsensus Price Target$13.00 (+1,429.8% Upside)Volume407,594 sharesAverage Volume305,016 shares13. Rani Therapeutics NASDAQ:RANI$0.56 +0.01 (+0.97%) As of 06/4/2025 04:00 PM EasternRani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani TherapeuticsMarket Capitalization$32.18 millionP/E Ratio-0.53Consensus RatingBuyConsensus Price Target$9.40 (+1,578.9% Upside)Volume292,392 sharesAverage Volume803,055 shares14. Context Therapeutics NASDAQ:CNTX$0.58 -0.01 (-1.15%) As of 06/4/2025 04:00 PM EasternContext Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$51.61 millionP/E Ratio-0.63Consensus RatingBuyConsensus Price Target$6.00 (+942.9% Upside)Volume98,639 sharesAverage Volume290,510 shares15. Stardust Power NASDAQ:SDST$0.64 -0.01 (-2.10%) As of 06/4/2025 04:00 PM EasternStardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.Market Capitalization$38.74 millionP/E Ratio-0.87Consensus RatingBuyConsensus Price Target$5.11 (+693.9% Upside)Volume310,624 sharesAverage Volume398,736 shares16. Gain Therapeutics NASDAQ:GANX$1.99 -0.02 (-1.00%) As of 06/4/2025 04:00 PM EasternGain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain TherapeuticsMarket Capitalization$60.19 millionP/E Ratio-1.81Consensus RatingBuyConsensus Price Target$8.20 (+312.1% Upside)Volume194,133 sharesAverage Volume311,209 shares17. Nkarta NASDAQ:NKTX$1.89 +0.12 (+6.78%) As of 06/4/2025 04:00 PM EasternNkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More about NkartaMarket Capitalization$134.11 millionP/E Ratio-1.01Consensus RatingBuyConsensus Price Target$14.67 (+676.0% Upside)Volume541,635 sharesAverage Volume1.06 million shares18. ProQR Therapeutics NASDAQ:PRQR$1.81 +0.03 (+1.69%) As of 06/4/2025 04:00 PM EasternProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More about ProQR TherapeuticsMarket Capitalization$190.44 millionP/E Ratio-5.66Consensus RatingBuyConsensus Price Target$8.00 (+342.0% Upside)Volume153,582 sharesAverage Volume633,133 shares19. Zura Bio NASDAQ:ZURA$1.18 +0.11 (+10.28%) As of 06/4/2025 04:00 PM EasternZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. More about Zura BioMarket Capitalization$80.68 millionP/E Ratio-1.69Consensus RatingBuyConsensus Price Target$14.33 (+1,114.7% Upside)Volume953,817 sharesAverage Volume419,785 shares20. Aclaris Therapeutics NASDAQ:ACRS$1.61 +0.14 (+9.52%) As of 06/4/2025 04:00 PM EasternAclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris TherapeuticsMarket Capitalization$174.33 millionP/E Ratio-3.10Consensus RatingBuyConsensus Price Target$9.71 (+503.4% Upside)Volume1.69 million sharesAverage Volume1.19 million shares21. Erasca NASDAQ:ERAS$1.53 +0.09 (+5.88%) As of 06/4/2025 04:00 PM EasternErasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. More about ErascaMarket Capitalization$433.43 millionP/E Ratio-1.84Consensus RatingBuyConsensus Price Target$4.57 (+198.8% Upside)Volume1.97 million sharesAverage Volume1.73 million shares22. SAB Biotherapeutics NASDAQ:SABS$1.87 +0.01 (+0.40%) As of 06/4/2025 03:44 PM EasternSAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. More about SAB BiotherapeuticsMarket Capitalization$17.35 millionP/E Ratio-0.50Consensus RatingBuyConsensus Price Target$12.20 (+553.3% Upside)Volume18,280 sharesAverage Volume66,909 shares23. TScan Therapeutics NASDAQ:TCRX$1.78 +0.03 (+1.71%) As of 06/4/2025 04:00 PM EasternTScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. More about TScan TherapeuticsMarket Capitalization$99.03 millionP/E Ratio-1.68Consensus RatingBuyConsensus Price Target$7.80 (+338.2% Upside)Volume410,817 sharesAverage Volume411,518 shares24. Artiva Biotherapeutics NASDAQ:ARTV$1.97 +0.02 (+1.03%) As of 06/4/2025 04:00 PM EasternArtiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. More about Artiva BiotherapeuticsMarket Capitalization$48.00 millionConsensus RatingBuyConsensus Price Target$19.40 (+884.8% Upside)Volume74,451 sharesAverage Volume170,453 sharesToday's Range$1.91▼$1.9925. Cresco Labs OTCMKTS:CRLBF$0.51 -0.06 (-9.73%) As of 06/4/2025 03:59 PM EasternCresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. More about Cresco LabsMarket Capitalization$250.42 millionP/E Ratio-2.55Consensus RatingBuyVolume2.44 million sharesAverage Volume654,059 sharesToday's Range$0.49▼$0.60 More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Stock Keeps Giving Investors Reasons To Buy CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause? Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
